论文部分内容阅读
目的:分析PVA联合重组人血管内皮抑素介入治疗子宫腺肌症的临床疗效。方法:选取根据临床症状以彩色多普勒检查确诊为子宫腺肌症的患者共78例作为研究对象,将患者随机分为观察组和对照组各39例,观察组给予PVA联合重组人血管内皮抑素进行介入治疗,对照组给予单纯重组人血管内皮抑素治疗,比较两组患者治疗前、后的痛经程度、月经量、子宫体积等指标以及卵巢功能。结果:两组患者治疗前的痛经程度、月经量以及子宫体积等指标差异无统计学意义(P>0.05);但经相应治疗6个月后,两组患者的痛经程度、月经量以及子宫体积等指标均有明显改善,且观察组比对照组更加明显,差异有统计学意义(P<0.05);观察组患者治疗前以及治疗后3、6个月的血FS、LH、E2、P、T以及PHL等卵巢功能指标水平差异无统计学意义(P>0.05)。结论:PVA联合重组人血管内皮抑素介入治疗子宫腺肌症的近期临床疗效显著,具有较好的安全性,且对卵巢功能无明显影响,值得临床应用和推广。
Objective: To analyze the clinical efficacy of PVA combined with recombinant human endostatin in the treatment of adenomyosis. Methods: A total of 78 patients with adenomyosis confirmed by color Doppler imaging were selected as the research objects. The patients were randomly divided into observation group and control group, 39 cases each. The observation group was given PVA combined with recombinant human vascular endothelial Patients in the control group were treated with recombinant human endostatin. The levels of dysmenorrhea, menstrual flow, uterine volume and ovarian function before and after treatment in both groups were compared. Results: There was no significant difference in dysmenorrhea, menstrual flow and uterine volume between the two groups before treatment (P> 0.05). However, after 6 months of treatment, the degree of dysmenorrhea, menstrual flow and uterine volume (P <0.05). The levels of FS, LH, E2, P in the observation group before treatment and 3 and 6 months after treatment were significantly higher in the observation group than those in the control group T and PHL and other indicators of ovarian function was no significant difference (P> 0.05). Conclusion: The recent clinical efficacy of PVA combined with recombinant human endostatin in the treatment of adenomyosis is significant, with good safety and no significant effect on ovarian function, which is worthy of clinical application and promotion.